Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Assessment of immunogenicity and drug activity in patient sera by flow-induced dispersion analysis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. A new method to quantify left ventricular mass by 2D echocardiography

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Multi-modal and multi-scale clinical retinal imaging system with pupil and retinal tracking

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Low adherence to the guideline for the acute treatment of migraine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Biochemical abnormalities among patients referred for celiac disease antibody blood testing in a primary health care setting

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. CXCL13 predicts long term radiographic status in early rheumatoid arthritis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Rheumatology: Biosimilars are here to stay

    Publikation: Bidrag til tidsskriftLederForskningpeer review

  3. Waiting for JAK inhibitor safety data

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Biopharmaceuticals have revolutionized the treatment of many diseases such as diabetes, cancer, and autoimmune disorders. These complex entities provide unique advantages like high specificity towards their target. Unfortunately, biopharmaceuticals are also prone to elicit undesired immunogenic responses (immunogenicity), compromising treatment efficacy as well as patient safety due to severe adverse effects including life threatening conditions. Current immunogenicity assays are hampered by immobilization procedures, complicated sample pre-treatment, or rely on cell-based methods which all prevent reliable and continuous monitoring of patients. In this work, we present Flow Induced Dispersion Analysis (FIDA) for assessment of immunogenicity and drug activity in serum samples from arthritis patients receiving adalimumab. FIDA is a first principle technique for size-based characterization of biomolecules and their complexes under biologically relevant conditions. The FIDA methodology rely on an absolute and quantitative readout (hydrodynamic radius) thus reducing the need for positive and negative controls. Here, FIDA is applied for evaluating active adalimumab in serum by studying the interaction with its target tumor necrosis factor alpha (TNF-α). We report proof of principle for a quantitative approach for stratifying patients exhibiting presence of neutralizing and non-neutralizing antibodies based on their individual drug activity pattern. Further, it can be applied to any biopharmaceutical having soluble drug targets and it holds potential in a companion diagnostics setting.

OriginalsprogEngelsk
Artikelnummer4670
TidsskriftScientific Reports
Vol/bind12
Udgave nummer1
Sider (fra-til)4670
ISSN2045-2322
DOI
StatusUdgivet - 2022

Bibliografisk note

© 2022. The Author(s).

ID: 75715379